Xortx Therapeutics Stock Analysis
| XRTX Stock | USD 1.27 0.06 4.96% |
XORTX Therapeutics is undervalued with Real Value of 2.48 and Target Price of 6.16. The main objective of XORTX Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what XORTX Therapeutics is worth, separate from its market price. There are two main types of XORTX Therapeutics' stock analysis: fundamental analysis and technical analysis.
The XORTX Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. XORTX Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. XORTX Stock trading window is adjusted to America/New York timezone.
XORTX |
XORTX Stock Analysis Notes
The company has Price to Book (P/B) ratio of 1.92. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. XORTX Therapeutics has Price/Earnings (P/E) ratio of 170.67. The entity last dividend was issued on the January 31, 2014. The firm had 1:9 split on the 14th of November 2023. XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. Xortx Therapeutics is traded on NASDAQ Exchange in the United States. For more information please call Allen Davidoff at 403 455 7727 or visit https://www.xortx.com.XORTX Therapeutics Investment Alerts
| XORTX Therapeutics generated a negative expected return over the last 90 days | |
| XORTX Therapeutics has high historical volatility and very poor performance | |
| XORTX Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XORTX Therapeutics currently holds about 13.42 M in cash with (6.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03. | |
| XORTX Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: XORTX Therapeutics files to sell 810,810 common shares for holders |
XORTX Therapeutics Upcoming and Recent Events
Earnings reports are used by XORTX Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
XORTX Largest EPS Surprises
Earnings surprises can significantly impact XORTX Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.1456 | -0.11 | 0.0356 | 24 | ||
2023-03-31 | 2022-12-31 | -0.27 | -0.2 | 0.07 | 25 | ||
2022-05-12 | 2022-03-31 | -0.19 | -0.26 | -0.07 | 36 |
XORTX Stock Institutional Investors
| Shares | Royal Bank Of Canada | 2024-06-30 | 1.2 K | Advisor Group Holdings, Inc. | 2024-06-30 | 1.2 K | Hartland & Co | 2024-06-30 | 277 | Jpmorgan Chase & Co | 2024-06-30 | 254 | Bank Of Montreal | 2024-06-30 | 0.0 | Bmo Capital Markets Corp. | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
XORTX Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.34 M.XORTX Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.94) | (0.89) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (0.47) | (0.49) |
Management Efficiency
XORTX Therapeutics has return on total asset (ROA) of (0.3314) % which means that it has lost $0.3314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2936) %, meaning that it created substantial loss on money invested by shareholders. XORTX Therapeutics' management efficiency ratios could be used to measure how well XORTX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to rise to -0.89 in 2024. At this time, XORTX Therapeutics' Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to rise to about 189 K in 2024, whereas Total Assets are likely to drop slightly above 5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.09 | 1.66 | |
| Tangible Book Value Per Share | 3.00 | 3.15 | |
| Enterprise Value Over EBITDA | (0.36) | (0.38) | |
| Price Book Value Ratio | 0.94 | 0.89 | |
| Enterprise Value Multiple | (0.36) | (0.38) | |
| Price Fair Value | 0.94 | 0.89 | |
| Enterprise Value | 2.3 M | 2.2 M |
Understanding the operational decisions made by XORTX Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta (0.21) | Return On Assets (0.33) | Return On Equity (0.29) |
Technical Drivers
As of the 30th of November, XORTX Therapeutics maintains the Downside Deviation of 7.87, mean deviation of 7.45, and Market Risk Adjusted Performance of 0.5473. In relation to fundamental indicators, the technical analysis model lets you check available technical drivers of XORTX Therapeutics, as well as the relationship between them.XORTX Therapeutics Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. XORTX Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for XORTX Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
XORTX Therapeutics Outstanding Bonds
XORTX Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. XORTX Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XORTX bonds can be classified according to their maturity, which is the date when XORTX Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
XORTX Therapeutics Predictive Daily Indicators
XORTX Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of XORTX Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
XORTX Therapeutics Forecast Models
XORTX Therapeutics' time-series forecasting models are one of many XORTX Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary XORTX Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About XORTX Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how XORTX Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling XORTX shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as XORTX Therapeutics. By using and applying XORTX Stock analysis, traders can create a robust methodology for identifying XORTX entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current XORTX Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. XORTX analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. XORTX analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 6.16 | Strong Buy | 1 | Odds |
Most XORTX analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand XORTX stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of XORTX Therapeutics, talking to its executives and customers, or listening to XORTX conference calls.
XORTX Stock Analysis Indicators
XORTX Therapeutics stock analysis indicators help investors evaluate how XORTX Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading XORTX Therapeutics shares will generate the highest return on investment. By understating and applying XORTX Therapeutics stock analysis, traders can identify XORTX Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 10.4 M | |
| Common Stock Shares Outstanding | 2 M | |
| Total Stockholder Equity | 4.6 M | |
| Property Plant And Equipment Net | 23.9 K | |
| Cash And Short Term Investments | 3.4 M | |
| Cash | 3.4 M | |
| Accounts Payable | 195.8 K | |
| Net Debt | -3.4 M | |
| 50 Day M A | 1.5809 | |
| Total Current Liabilities | 294.9 K | |
| Other Operating Expenses | 3.2 M | |
| Non Current Assets Total | 1.4 M | |
| Forward Price Earnings | 0.9621 | |
| Non Currrent Assets Other | 1.2 M | |
| Stock Based Compensation | 121 K |
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.